308 related articles for article (PubMed ID: 15215254)
1. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
Alce TM; Popik W
J Biol Chem; 2004 Aug; 279(33):34083-6. PubMed ID: 15215254
[TBL] [Abstract][Full Text] [Related]
2. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
Schäfer A; Bogerd HP; Cullen BR
Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
[TBL] [Abstract][Full Text] [Related]
3. The interaction between HIV-1 Gag and APOBEC3G.
Cen S; Guo F; Niu M; Saadatmand J; Deflassieux J; Kleiman L
J Biol Chem; 2004 Aug; 279(32):33177-84. PubMed ID: 15159405
[TBL] [Abstract][Full Text] [Related]
4. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
[TBL] [Abstract][Full Text] [Related]
5. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
Luo K; Liu B; Xiao Z; Yu Y; Yu X; Gorelick R; Yu XF
J Virol; 2004 Nov; 78(21):11841-52. PubMed ID: 15479826
[TBL] [Abstract][Full Text] [Related]
6. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
7. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.
Burnett A; Spearman P
J Virol; 2007 May; 81(10):5000-13. PubMed ID: 17344295
[TBL] [Abstract][Full Text] [Related]
9. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
Mangeat B; Turelli P; Liao S; Trono D
J Biol Chem; 2004 Apr; 279(15):14481-3. PubMed ID: 14966139
[TBL] [Abstract][Full Text] [Related]
11. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
12. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
13. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
Zennou V; Perez-Caballero D; Göttlinger H; Bieniasz PD
J Virol; 2004 Nov; 78(21):12058-61. PubMed ID: 15479846
[TBL] [Abstract][Full Text] [Related]
14. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
[TBL] [Abstract][Full Text] [Related]
15. Functional domains of APOBEC3G required for antiviral activity.
Li J; Potash MJ; Volsky DJ
J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
[TBL] [Abstract][Full Text] [Related]
16. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
17. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
18. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
19. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Conticello SG; Harris RS; Neuberger MS
Curr Biol; 2003 Nov; 13(22):2009-13. PubMed ID: 14614829
[TBL] [Abstract][Full Text] [Related]
20. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
